Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
In one study, participants using Semaglutide alongside lifestyle changes lost an average of 15% of their body weight over 68 weeks
For example, modifying coverage can raise monthly insurance rates by $25 or more
Diabetes Care (2012) 35:122531
individual experience varies considerably
(Note: We do not accept Medicare or Medicaid)
US$ 24.35
US$ 26.50
US$ 29.18
US$ 28.42
US$ 27.91
US$ 20.09
US$ 22.09
US$ 29.95
US$ 22.66
.png.jpg)
